🇮🇱 Hu38Sb19 in Israel

Hu38Sb19 (isatuximab) regulatory status in Israel.

Marketing authorisation

MOH

  • Status: likely_approved

Hu38Sb19 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in Israel

Frequently asked questions

Is Hu38Sb19 approved in Israel?

Yes. MOH has authorised it.

Who is the marketing authorisation holder for Hu38Sb19 in Israel?

Sanofi is the originator. The local marketing authorisation holder may differ — check the official source linked above.